Resection of hepatic metastases from colorectal cancer.

Archives of Surgery (Impact Factor: 4.3). 07/1984; 119(6):647-51.
Source: PubMed

ABSTRACT We studied 141 patients who had resection of hepatic metastases from colorectal cancer, considering all such lesions removed between 1948 and 1982. The study involved extended observations of patients described previously. Also included were 21 patients who had wedge resections of small metastases done since 1976, who, therefore, did not qualify for analysis of major hepatic resections reported recently (1980 and 1983). The overall five-year survival rate was 25%, significantly higher than that of a group of historical controls who had resectable metastases that were not removed. The size and nature of our extended sample allowed identification of some determinants of favorable prognosis: Dukes' stage of the primary lesion, absence of extrahepatic metastases, and being female. Contrary to our earlier observations, this study justified removal of some multiple hepatic metastases.

  • [Show abstract] [Hide abstract]
    ABSTRACT: For the 20% of patients with resectable colorectal liver metastases (CRLM), hepatic resection is safe, effective and potentially curative. Factors related to the primary and metastatic tumors individually and in clinical risk-scoring schemes are the best prognostic factors, although it is difficult to define patient groups with resectable, liver-limited CRLM that should be excluded from surgery. Systemic chemotherapy for metastatic colorectal cancer has improved but does not improve overall survival as adjuvant therapy after resection. Conversion to complete resection with systemic and/or hepatic arterial infusion chemotherapy is an appropriate goal for patients with unresectable CRLM. Copyright © 2015 Elsevier Inc. All rights reserved.
    Hematology/Oncology Clinics of North America 02/2015; 29(1):61-84. DOI:10.1016/j.hoc.2014.09.003 · 2.07 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatic metastasectomy for patients with primary colorectal cancer offers better long-term outcome, and chemotherapy can increase the rate of hepatic resectability for patients with initially inoperable disease. The pattern of liver metastasis and status of the primary tumor are rarely discussed in the analysis of long-term outcome. In this report, we evaluate the influence of the pattern of metastasis on clinical features and prognosis. One hundred and fifty-nine patients who underwent hepatic metastasectomy with curative intent for liver metastasis of colorectal cancer between October 1991 and December 2006 were enrolled. Patients were grouped according to whether liver metastasis was centrally or peripherally located, based on imaging and operative findings. Patient demographics, characteristics of the primary and metastatic tumors, and surgical outcomes were analyzed for long-term survival. A greater proportion of patients with centrally located metastases were male, as compared with those with peripherally located metastases. Compared with patients with peripherally located metastases, patients with centrally located metastases were more likely to have multiple lesions (P = 0.016), involvement of multiple segments (P = 0.006), large metastases (P < 0.001), and bilobar distribution of metastases (P < 0.001). The estimated 5-year recurrence-free and overall survival rates were 22.4% and 34.2%, respectively. Univariate analysis revealed that centrally located metastasis, primary tumor in the transverse colon, metastasis in regional lymph nodes, initial extrahepatic metastasis, synchronous liver metastasis, multiple lesions, poorly differentiated tumor, and resection margin <10 mm were significant poor prognostic factors for recurrence-free survival and overall survival. Cox regression analysis showed that inadequate resection margin and centrally located liver metastasis were significant predictors of shorter overall survival. In colorectal cancer, centrally located liver metastasis represents a poor prognostic factor after hepatectomy, and is associated with early recurrence. Neoadjuvant chemotherapy may be used to downstage centrally located liver metastases to improve outcome.
    World Journal of Surgical Oncology 12/2015; 13(1):497. DOI:10.1186/s12957-015-0497-6 · 1.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The liver is a common site of malignant disease with hepatocellular carcinoma and liver metastases accounting for the majority of liver malignancies. Conventional treatment options are confined to chemotherapy, surgery and minimally invasive procedures such as radiofrequency ablation. External beam radiation therapy has a limited role in the treatment of liver malignancy, mainly due to the substantial risk of radiation-induced liver disease. Transarterial chemoembolisation is contraindicated in patients with portal vein thrombosis or advanced liver disease. Selective internal radiation therapy using yttrium-90 microspheres has emerged as a suitable treatment of liver tumours. In this review we discuss the principles behind this treatment, the process of patient selection, and the method of dose calculation and administration. We also highlight possible adverse effects and review the literature for data on response assessment and long-term outcome.
    04/2014; 2(2):165-182. DOI:10.1007/s40336-013-0046-7

Duane M. Ilstrup